###begin article-title 0
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
Sequence Variation in DDAH1 and DDAH2 Genes Is Strongly and Additively Associated with Serum ADMA Concentrations in Individuals with Type 2 Diabetes
###end article-title 0
###begin p 1
Conceived and designed the experiments: SA KB NK NP JEC. Performed the experiments: SA AK SJ MJW. Analyzed the data: SA KB SJ MJW NK NP JEC. Contributed reagents/materials/analysis tools: AK MJW JEC. Wrote the paper: SA KB AK SJ NK NP JEC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
Asymmetric dimethylarginine (ADMA), present in human serum, is an endogenous inhibitor of nitric oxide synthase and contributes to vascular disease. Dimethylarginine dimethylaminohydrolase (DDAH) is an ADMA degrading enzyme that has two isoforms: DDAHI and DDAHII. We sought to determine whether serum ADMA levels in type 2 diabetes are influenced by common polymorphisms in the DDAH1 and DDAH2 genes.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 391 395 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 504 506 504 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 531 533 531 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 644 654 644 654 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TGCCCAGGAG</named-content>
###xml 932 937 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 953 958 953 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 1011 1013 1011 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 117 129 <span type="species:ncbi:9606">participants</span>
###xml 849 861 <span type="species:ncbi:9606">participants</span>
Relevant clinical parameters were measured and peripheral whole blood obtained for serum and genetic analysis on 343 participants with type 2 diabetes. Serum ADMA concentrations were determined by mass spectroscopy. Twenty six tag SNPs in the DDAH1 and 10 in the DDAH2 gene were genotyped in all subjects and tested for association with serum ADMA levels. Several SNPs and haplotypes in the DDAH genes were strongly associated with ADMA levels. Most significantly in the DDAH1 gene, rs669173 (p = 2.96x10-7), rs7521189 (p = 6.40x10-7), rs2474123 (p = 0.00082) and rs13373844 (p = 0.00027), and in the DDAH2 gene, rs3131383 (p = 0.0029) and the TGCCCAGGAG haplotype (p = 0.0012) were significantly associated with ADMA levels. Sub-analysis by diabetic retinopathy (DR) status revealed these variants were associated with ADMA levels predominantly in participants without DR. Combined analysis of the most strongly associated SNPs in DDAH1 (rs669173) and DDAH2 (rs3131383) revealed an additive effect (p = 1.37x10-8) on ADMA levels.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
Genetic variation in the DDAH1 and 2 genes is significantly associated with serum ADMA levels. Further studies are required to determine the pathophysiological significance of elevated serum ADMA in type 2 diabetes and to better understand how DDAH gene variation influences ADMA levels.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 367 370 367 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Dimmeler1">[1]</xref>
###xml 372 375 372 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Wang1">[2]</xref>
###xml 411 414 411 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Stamler1">[3]</xref>
###xml 416 419 416 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Oelze1">[4]</xref>
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), the key endothelial enzyme that converts L-arginine to L-citrulline and nitric oxide (NO). Endothelium-derived NO helps to maintain vascular homeostasis through vasodilatation, suppression of inflammation and inhibition of the proliferation of vascular smooth muscle cells [1], [2], platelet adhesion and aggregation [3], [4].
###end p 9
###begin p 10
###xml 82 85 82 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abbasi1">[5]</xref>
###xml 322 325 322 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Toda1">[6]</xref>
###xml 374 377 374 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abbasi1">[5]</xref>
###xml 423 426 423 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Makino1">[7]</xref>
###xml 428 431 428 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Malecki1">[8]</xref>
###xml 433 436 433 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Sugai1">[9]</xref>
###xml 438 442 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abhary1">[10]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abhary1">[10]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Hanai1">[11]</xref>
ADMA levels have been shown to be increased in individuals with diabetes mellitus [5]. Endothelial dysfunction, such as occurs in hyperglycemia, is associated with decreased NOS activity and NO bioavailability resulting in vasoconstriction and increased reactive oxygen species. This leads to impaired ocular hemodynamics [6]. Recently, elevated serum ADMA in both diabetes [5] and its complications, including retinopathy [7], [8], [9], [10] and nephropathy [10], [11], have been reported.
###end p 10
###begin p 11
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Achan1">[12]</xref>
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Teerlink1">[13]</xref>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Tran1">[14]</xref>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 508 512 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Leiper1">[15]</xref>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Tran2">[16]</xref>
###xml 571 575 571 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Tran2">[16]</xref>
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
Dimethylarginine dimethylaminohydrolase (DDAH) is the enzyme responsible for the degradation of ADMA into citrulline and dimethylamine [12], [13]. Over 90% of endogenous ADMA is metabolised by DDAH with the remainder renally excreted [14]. DDAH is expressed as two isoforms encoded by different genes. DDAHI predominates in tissues expressing neuronal NOS (nNOS), and is encoded by the DDAH1 (OMIM#604743) gene on chromosome 1p22. DDAHII is found in highly vascular tissues expressing endothelial NOS (eNOS) [15], [16], and immune tissues expressing inducible NOS (iNOS) [16], and is encoded by the DDAH2 (OMIM#604744) gene on chromosome 6p21.3.
###end p 11
###begin p 12
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Dayoub1">[17]</xref>
###xml 288 293 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 429 434 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 439 444 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-WojciakStothard1">[18]</xref>
###xml 157 172 <span type="species:ncbi:10090">transgenic mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
Evidence for the metabolic control of ADMA by DDAH genes, and their influence on endothelial cells has been provided by animal studies. DDAH1 overexpressing transgenic mice had a two fold reduction in plasma ADMA associated with a 2 fold increase in tissue NOS activity [17]. Conversely, DDAH1 knockout mice had increased pulmonary endothelial permeability as a result of ADMA elevation, which was prevented by overexpression of DDAH1 and DDAH2 in endothelial cells [18].
###end p 12
###begin p 13
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
We aimed to determine whether serum ADMA levels are influenced by common single nucleotide polymorphisms (SNPs) in DDAH1 and DDAH2 genes in a large Australian cohort of individuals with type 2 diabetes, and found that genetic variation in the DDAH1 and DDAH2 genes significantly and additively affects serum ADMA concentrations.
###end p 13
###begin title 14
Results
###end title 14
###begin p 15
###xml 225 232 225 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t001">Table 1</xref>
###xml 30 42 <span type="species:ncbi:9606">participants</span>
###xml 203 215 <span type="species:ncbi:9606">participants</span>
Three hundred and forty three participants with type 2 diabetes were included. Disease duration, smoking, nephropathy and diabetic retinopathy were significantly associated with serum ADMA levels in all participants (p<0.05, Table 1). These variables were subsequently adjusted for in multivariate analyses. Subjects with no retinopathy (n = 225) were more likely to be female, had shorter duration of disease, significantly lower HbA1c levels and less nephropathy when compared to subjects with blinding diabetic retinopathy (n = 118, data not shown).
###end p 15
###begin title 16
###xml 86 98 <span type="species:ncbi:9606">participants</span>
Clinical characteristics [number of subjects (%) or mean+/-standard deviation] of all participants and associations with serum ADMA levels.
###end title 16
###begin p 17
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
###xml 155 162 155 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
###xml 167 175 167 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 343 345 343 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 760 765 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 906 913 906 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
Several SNPs in the DDAH genes were significantly associated with serum ADMA levels after adjusting for associated variables in the multivariate analyses (Table 2 and Figure 1), with the most significant in DDAH1 being rs669173 [p = 2.96x10-7 in the genotypic model, Beta coefficient (B): -0.03, 95% CI: -0.04 to -0.02], rs7521189 (p = 6.40x10-7 in the additive model, B: -0.03, 95% CI: -0.04 to -0.01), rs2474123 (p = 0.00082 in the additive model, B: 0.02, 95%CI: 0.01-0.04), rs13373844 (p = 0.00027 in the dominant model, B: -0.03, 95% CI: -0.05 to -0.02) and rs986639 (p = 0.0015 in the genotypic model, B: 0.03, 95% CI: 0.01-0.05). The SNPSpD method for multiple testing correction in SNP association studies estimated a total of 17 independent tests for DDAH1 analyses and after correcting for multiple testing, the SNPs listed above remained significantly associated with serum ADMA levels (p<0.03, Table 2).
###end p 17
###begin title 18
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH I</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
Idiogram of significantly associated SNPs and haplotypes of DDAH I (1A) and DDAH II (1B) with serum ADMA levels.
###end title 18
###begin p 19
Scales of genomic regions are estimates. P values are presented for significant SNPs and haplotype associations have been adjusted for disease duration, age, hypertension, smoking, nephropathy and diabetic retinopathy.
###end p 19
###begin title 20
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
###xml 63 75 <span type="species:ncbi:9606">participants</span>
Association of DDAH tag SNPs and with serum ADMA levels in all participants.
###end title 20
###begin p 21
###xml 186 198 <span type="species:ncbi:9606">participants</span>
Note: p values have been adjusted for duration of diabetes, age, hypertension, smoking, nephropathy and retinopathy status. Results are shown only if genotypes were carried by 5 or more participants. Significant p values are shown in bold type.
###end p 21
###begin p 22
*  =  p-values survive correction for multiple testing.
###end p 22
###begin p 23
dagger  =  p values are also significant in no diabetic retinopathy subset.
###end p 23
###begin p 24
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 144 151 144 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
###xml 156 164 156 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 396 403 396 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
###xml 382 394 <span type="species:ncbi:9606">participants</span>
SNP rs3131383 in DDAH2 was significantly associated with serum ADMA levels (p = 0.0029 in the dominant model, B: -0.03, 95% CI: -0.06 to -0.01, Table 2 and Figure 1). Seven independent tests for DDAH2 were estimated by the SNPSpD method and after correcting for multiple testing, rs3131383 (p = 0.034 in the dominant model) remained significantly associated with ADMA levels in all participants (Table 2).
###end p 24
###begin p 25
###xml 253 255 253 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 463 470 463 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
###xml 765 772 765 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
###xml 812 817 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 166 178 <span type="species:ncbi:9606">participants</span>
Sub-analysis by diabetic retinopathy status in the multivariate analyses revealed the majority of these SNPs to be associated with ADMA level only in the subgroup of participants that had no diabetic retinopathy, most significantly rs669173 (p = 4.66x10-5 in the additive model, B: -0.05, 95% CI: -0.08 to -0.03), rs2474123 (p = 0.00086 in the additive model, B: 0.04, 95% CI: 0.01-0.06) and rs7521189 (p = 0.0027 in the additive model, B: -0.03, -0.06 to -0.01, Table 2). These SNPs remained significant after correction for multiple testing. In the blinding diabetic retinopathy cases, rs669173 (p = 0.017 in the additive model), and rs7521189 (p = 0.023 in the additive model) were nominally significant, however did not survive correction for multiple testing (Table 2). Although association of rs3131383 in DDAH2 with ADMA level was not statistically significantly associated in the smaller blinding retinopathy group, the direction of the association with ADMA was the same as that for no retinopathy controls and the full dataset (p = 0.143, B: -0.03 95% CI: -0.07-0.01).
###end p 25
###begin p 26
###xml 388 397 388 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009462.s001">Table S1B</xref>
###xml 561 564 561 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;08</sup>
###xml 600 607 600 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t003">Table 3</xref>
###xml 659 660 659 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 740 741 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 764 765 764 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
To assess whether there are additive effects of polymorphisms in the two genes on serum ADMA, the total number of minor alleles of the most significantly associated SNP in each gene (rs669173 and rs3131383) was counted in each individual and included in the linear regression along with the clinical covariates. Multiple minor alleles were associated with lower serum ADMA (Supplementary Table S1B). The total number of minor alleles of the two SNPs was significantly associated with ADMA serum level after adjusting for relevant clinical variables (p = 1.37x10-08, B: -0.03, 95% CI: -0.04 to -0.02, Table 3). This model accounted for more of the variation (r2 = 0.147) than including each SNP in the regression as a separate factor with (r2 = 0.119) or without (r2 = 0.119) an interaction term between the two SNPs. Thus the two genes appear to influence ADMA levels additively.
###end p 26
###begin title 27
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 142 154 <span type="species:ncbi:9606">participants</span>
Association of the combination of the most significantly associated DDAH1 (rs669173) and DDAH2 (rs3131383) SNPs with serum ADMA levels in all participants.
###end title 27
###begin p 28
B = beta coefficient.
###end p 28
###begin p 29
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 148 155 148 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t004">Table 4</xref>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 504 511 504 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t004">Table 4</xref>
###xml 516 524 516 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>
###xml 535 545 535 545 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TATAGTGGAG</named-content>
###xml 656 663 656 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t004">Table 4</xref>
###xml 670 680 670 680 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TGCCCAGGAG</named-content>
###xml 684 689 684 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 787 794 787 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t004">Table 4</xref>
###xml 799 807 799 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>
###xml 877 884 877 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t004">Table 4</xref>
###xml 965 970 965 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 1010 1015 1010 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 1110 1117 1110 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t004">Table 4</xref>
For the haplotype analyses, observation of the DDAH SNPs in HapMap revealed three blocks of linkage disequilibrium in DDAH1 and one block in DDAH2 (Table 4). As block 2 of DDAH1 consisted of 11 tag SNPs, it was further subdivided into two blocks for the haplotype analyses. After adjusting for associated variables in the multivariate analyses, several DDAH1 haplotypes were significantly associated with ADMA levels, with the GAATTT haplotype of block 2A (p = 0.00012, B: -0.03, 95% CI: -0.04 to -0.01, Table 4 and Figure 1), and the TATAGTGGAG haplotype of block 3 (p = 0.00074, B: -0.02, 95% CI: -0.04 to -0.01) being the most significantly associated (Table 4). The TGCCCAGGAG of DDAH2 was significantly associated with serum ADMA levels (p = 0.0012 B: -0.03 95% CI: -0.05 to -0.01, Table 4 and Figure 1). Seven haplotypes remained significant after Bonferroni correction (Table 4). Sub-analysis by diabetic retinopathy status revealed 5 of these haplotypes in DDAH1 and the single associated haplotype in DDAH2 to be significantly associated with serum ADMA level in the no diabetic retinopathy subgroup (Table 4) in the multivariate analyses. No haplotypes were associated with ADMA level in the blinding diabetic retinopathy subgroup after correction for multiple testing.
###end p 29
###begin title 30
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
Association of common DDAH haplotypes (>2% frequency) with ADMA levels.
###end title 30
###begin p 31
###xml 53 60 53 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
Note: SNPs correspond to the order of those shown in Table 2. P values have been adjusted for duration of diabetes, age, hypertension, smoking, nephropathy and retinopathy status. Significant p values are shown in bold type.
###end p 31
###begin p 32
*  =  p values survive correction for multiple testing.
###end p 32
###begin p 33
dagger  =  p values are also significant in no diabetic retinopathy subset.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 121 133 <span type="species:ncbi:9606">participants</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
This study found genetic variation in the DDAH1 and DDAH2 genes to be significantly associated with serum ADMA levels in participants with type 2 diabetes. To our knowledge, this is the first study of its kind to investigate genetic variation in DDAH genes and their association with serum ADMA levels in patients with type 2 diabetes.
###end p 35
###begin p 36
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Duplain1">[19]</xref>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Shankar1">[20]</xref>
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Shankar1">[20]</xref>
###xml 303 306 303 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abbasi1">[5]</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Stuhlinger1">[21]</xref>
###xml 463 467 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Sydow1">[22]</xref>
###xml 544 549 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 641 645 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Sydow1">[22]</xref>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Lin1">[23]</xref>
###xml 829 833 829 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Forbes1">[24]</xref>
###xml 1003 1007 1003 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Ito1">[25]</xref>
###xml 1060 1064 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-MacAllister1">[26]</xref>
###xml 1102 1107 1102 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 1134 1138 1134 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Jones1">[27]</xref>
###xml 1187 1192 1187 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 1296 1300 1296 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Sakurada1">[28]</xref>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
###xml 338 344 <span type="species:ncbi:9606">humans</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 562 577 <span type="species:ncbi:10090">transgenic mice</span>
###xml 918 923 <span type="species:ncbi:9606">human</span>
###xml 1216 1219 <span type="species:ncbi:10116">rat</span>
ADMA is an endogenous inhibitor of NOS and therefore NO bioavailability. The role of NO in the development of insulin resistance is supported by eNOS [19], [20] and nNOS [20] knockout mice studies. Similarly, previous studies have shown serum ADMA elevation to be significantly associated with diabetes [5] and insulin resistance [21] in humans. Animal studies have also supported the role of ADMA in insulin resistance, with DDAH expression shown to play a role [22]. When compared to wild type mice, in response to a glucose challenge, Sydow et al found DDAH1 transgenic mice to show a blunted increase in ADMA, plasma insulin and glucose [22]. Hyperglycemia has also been shown to lead to decreased DDAH activity and subsequent ADMA elevation [23]. A variety of other factors have also been shown to be involved in control of DDAH expression and activity. For example, oxidative stress and inflammation in cultured human endothelial cells decreases DDAH activity and upregulates ADMA synthesis [24], [25] subsequently leading to a reduction in NO synthesis [26]. Variation in the promoter region of DDAH2 influences its expression [27]. Increased NO has also been shown to upregulate DDAH2 expression in cultured rat aortic endothelial cells, indicating a possible positive feedback mechanism [28].
###end p 36
###begin p 37
###xml 67 70 67 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Toda1">[6]</xref>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Boger1">[29]</xref>
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Stuhlinger2">[30]</xref>
###xml 284 287 284 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Makino1">[7]</xref>
###xml 289 292 289 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Malecki1">[8]</xref>
###xml 294 297 294 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Sugai1">[9]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abhary1">[10]</xref>
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Leiper1">[15]</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Tran2">[16]</xref>
###xml 426 430 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Tran2">[16]</xref>
###xml 493 497 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Connell1">[31]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Carmo1">[32]</xref>
###xml 505 509 505 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Yuan1">[33]</xref>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-AbuElAsrar1">[34]</xref>
###xml 554 558 554 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Connell1">[31]</xref>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Carmo1">[32]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Yuan1">[33]</xref>
###xml 612 616 612 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-AbuElAsrar1">[34]</xref>
###xml 713 718 <span type="species:ncbi:9606">human</span>
NO is also a key player in protection against microvascular damage [6], and serum ADMA levels have been found to be increased in conditions associated with endothelial dysfunction, including hypertension, hypercholesterolemia, hyperhomocysteinemia [29], [30] and diabetic retinopathy [7], [8], [9], [10]. Although DDAHI is primarily expressed in tissues producing nNOS [15], [16] and DDAHII in tissues producing eNOS and iNOS [16], all three isoforms of NOS have been isolated from the retina [31], [32], [33], [34]. Decreased retinal expression of eNOS [31] and increased expression of iNOS [32], [33] and nNOS [34] have been shown to be associated with hyperglycemia and diabetic retinopathy in both animal and human studies.
###end p 37
###begin p 38
###xml 284 287 284 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Sugai1">[9]</xref>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
###xml 496 503 496 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">without</italic>
###xml 869 873 869 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abhary1">[10]</xref>
###xml 1349 1353 1349 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Tsai1">[35]</xref>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 747 759 <span type="species:ncbi:9606">participants</span>
ADMA is present in the aqueous humor of the human eye. In a recent proteomic study with relatively small numbers, aqueous humor and serum ADMA levels were significantly higher in subjects with diabetes and those with severe diabetic retinopathy when compared to non-diabetic controls [9]. Sub-analysis by diabetic retinopathy status in this study revealed serum ADMA levels to be associated with common genetic variation in DDAH genes, primarily in our cohort of individuals with type 2 diabetes without diabetic retinopathy. However, for the mostly significantly associated SNPs, the serum ADMA levels trend in the same direction, and a true association may exist in the smaller retinopathy cohort which is less powered to detect the effect. The participants with no diabetic retinopathy had significantly lower ADMA levels compared to those with diabetic retinopathy [10]. Although the lack of highly significant association in the retinopathy group is likely attributable to power, it is possible that other influences play a greater role in determining serum ADMA levels once microvascular damage has occurred. Impairment of ADMA metabolism may occur due to oxidative stress and inflammation involved in endothelial dysfunction and microvascular damage. However, some studies have found elevated retinal NO in proliferative diabetic retinopathy [35], therefore ADMA elevation may actually be a compensatory mechanism to decrease pathologically elevated NO. It remains unclear whether ADMA elevation in diabetic retinopathy is a causal association or occurs as a result of endothelial dysfunction, and these potential mechanisms are not mutually exclusive.
###end p 38
###begin p 39
Diabetic retinopathy is a debilitating complication of diabetes mellitus with a multifactorial pathogenesis and limited treatment options. Further prospective and functional studies investigating the pathophysiological significance of elevated serum ADMA in the development of diabetic retinopathy and other diabetes complications are required. Ultimately, if causal relationships are established, this could lead to design of future therapeutic or preventative strategies to correct NO levels in the ocular environment, thereby retarding or preventing the development of diabetic retinopathy.
###end p 39
###begin p 40
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLIC1</italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLIC1</italic>
###xml 547 551 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Ducharme1">[36]</xref>
###xml 553 557 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Fanucchi1">[37]</xref>
###xml 559 563 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Valenzuela1">[38]</xref>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLIC1</italic>
Many of the most significantly associated DDAH1 SNPs in this study are located in intron 1 of the gene. The significantly associated DDAH2 SNP (rs3131383), although within the block of linkage disequilibrium that contains DDAH2, is actually within the chloride intracellular channel 1 (CLIC1) gene and 6255 bp from the DDAH2 transcription start site. CLIC1 encodes chloride ion channels that regulate fundamental cellular processes including transepithelial transport, maintenance of intracellular pH, and regulation of cell volume and cell cycle [36], [37], [38]. No associations have been reported between CLIC1 and serum DDAH or ADMA. The associated SNPs in both genes could either tag functional SNPs that affect expression level (eg promoter or other regulatory variants), or coding variants that affect DDAH protein activity. Very few if any common coding variants have been reported in these genes and therefore deep resequencing may be required to determine if they do exist.
###end p 40
###begin p 41
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
In conclusion, genetic variation in DDAH1 and DDAH2 genes was found to be strongly and significantly associated with serum ADMA levels in patients with type 2 diabetes, especially in those without retinopathy. Further studies are required to assess DDAH sequence variation and its influence on DDAH activity and serum ADMA levels both in individuals with and without diabetes to increase understanding of this complex pathway in normal and pathogenic conditions.
###end p 41
###begin title 42
Methods
###end title 42
###begin title 43
Ethics Statement
###end title 43
###begin p 44
###xml 38 43 <span type="species:ncbi:9606">Human</span>
###xml 227 239 <span type="species:ncbi:9606">participants</span>
Ethics approval was obtained from the Human Research Ethics Committees of Flinders Medical Centre, Royal Adelaide Hospital and Queen Elizabeth Hospital in Adelaide, Australia, and written informed consent was obtained from all participants.
###end p 44
###begin title 45
Subject Recruitment
###end title 45
###begin p 46
###xml 217 229 <span type="species:ncbi:9606">Participants</span>
Subjects were recruited from ophthalmology and endocrinology outpatient clinics of three tertiary hospitals in metropolitan Adelaide, South Australia, initially to study the genetics of blinding diabetic retinopathy. Participants were over 18 years of age and were required to have type 2 diabetes of at least 5 years duration and be on oral hypoglycemic or insulin therapy.
###end p 46
###begin p 47
###xml 327 333 <span type="species:ncbi:9606">person</span>
###xml 343 354 <span type="species:ncbi:9606">participant</span>
###xml 604 615 <span type="species:ncbi:9606">participant</span>
A detailed questionnaire containing information regarding sex, age, ethnicity, age at diagnosis of diabetes, family diabetic history, co-existing risk factors, systemic complications of diabetes, ocular complications as a result of diabetic retinopathy, past ocular history, smoking history and alcohol intake was conducted in person for each participant. Renal function tests [serum creatinine, urine albumin and albumin:creatinine ratio and glomerular filtration rate (GFR)], serum cholesterol and HbA1c levels were obtained from a state-wide database. Three recent HbA1c levels were averaged for each participant. For those cases diagnosed with blinding DR, HbA1c levels at the time of the ocular complication were used, and for controls with DM, HbA1c levels immediately prior to recruitment were averaged.
###end p 47
###begin p 48
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-1">[39]</xref>
###xml 46 57 <span type="species:ncbi:9606">participant</span>
###xml 200 211 <span type="species:ncbi:9606">participant</span>
###xml 213 221 <span type="species:ncbi:9606">Patients</span>
###xml 683 695 <span type="species:ncbi:9606">Participants</span>
Peripheral whole blood was obtained from each participant and DNA extracted using the QiaAmp Blood Maxi Kit (Qiagen, Valencia, CA, USA). Blood pressure and body mass index (BMI) were measured in each participant. Patients were classified as hypertensive if they were on treatment for hypertension, or they had a blood pressure reading greater than or equal to 140/90 mmHg at the time of recruitment. Hypercholesterolemia was defined as total cholesterol of greater than 5.5 mmol/L, or current use of lipid lowering medication. Retinopathy status for the worst eye was clinically graded by an ophthalmologist according to the Early Treatment Diabetic Retinopathy Study criteria [39]. Participants were only included if they had either no retinopathy, or blinding retinopathy defined as severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, or clinically significant macular edema. Nephropathy was defined as the presence of microalbuminuria (30-300 mg/day) or macroalbuminuria (>300 mg/day).
###end p 48
###begin title 49
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH</italic>
DDAH SNP Selection and Genotyping
###end title 49
###begin p 50
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Barrett1">[40]</xref>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-2">[41]</xref>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH1</italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDAH2</italic>
###xml 447 454 447 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009462-t002">Table 2</xref>
###xml 492 493 492 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 517 518 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Using the tagger program implemented in Haploview 4.0 [40], tag single nucleotide polymorphisms (SNPs) across DDAH1 and DDAH2 genes, including the promoter region, were selected on the basis of linkage disequilibrium patterns observed in the Caucasian (CEU) samples genotyped as part of the International HapMap Project [41]. Only SNPs with minor allele frequency greater than 5% in HapMap were considered. Twenty six DDAH1 and 10 DDAH2 tag SNPs (Table 2) which captured all alleles with an r2 of at least 0.8 (mean r2 = 0.95), were genotyped in all individuals on the Sequenom iPLEX GOLD chemistry on an Autoflex Mass Spectrometer at the Australian Genome Research Facility, Brisbane, Australia.
###end p 50
###begin title 51
Measurement of Serum Concentrations of ADMA, SDMA and Arginine
###end title 51
###begin p 52
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Abhary1">[10]</xref>
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Schwedhelm1">[42]</xref>
###xml 309 310 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 406 407 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 408 409 406 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 465 466 463 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 467 468 465 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 49 61 <span type="species:ncbi:9606">participants</span>
Serum ADMA concentrations were determined in all participants [10] by liquid chromatography-tandem mass spectrometry of the butyl esters on an Applied Biosystems 3200 Q-Trap instrument (Applied Biosystems, Scoresby, Victoria), as described by Schwedhelm et al [42]. (R)Deuterated internal standards (98 atom% 2H isotopic purity) were purchased from Cambridge Isotope Laboratories (Andover, MA) and were L-[2H7]-arginine for arginine quantitation and 2,3,3,4,4,5,5-[2H7]-ADMA for ADMA analyses. The between-run coefficient of variation for ADMA was determined as 4.0% at a concentration of 0.48 micromol/L.
###end p 52
###begin title 53
Statistical Analyses
###end title 53
###begin p 54
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Purcell1">[43]</xref>
###xml 808 812 808 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Nyholt1">[44]</xref>
###xml 835 839 835 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009462-Li1">[45]</xref>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
Pearson correlation was undertaken for associations of clinical covariates with ADMA levels in SPSS (v15.0 SPSS Inc, Chicago, IL). Differences in clinical covariates between patients with and without diabetic retinopathy were calculated by Student's t-test or the chi-square test. ADMA levels were log transformed to approximate a normal distribution. Genotypic associations for all SNPs were assessed in PLINK (v1.06) [43]. Dominant, additive, recessive and genotypic models were considered with respect to the minor allele. Haplotypic analyses were performed in accordance with the observed linkage disequilibrium (LD) patterns in the Caucasian sample in HapMap. Multiple testing of individual SNPs was adjusted for using the Single Nucleotide Polymorphism Spectral Decomposition (SNPSpD) method of Nyholt [44] modified by Li and Ji [45] and Bonferroni correction was applied to haplotype analyses.
###end p 54
###begin title 55
Supporting Information
###end title 55
###begin p 56
(0.21 MB DOC)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin title 58
Refrences
###end title 58
###begin article-title 59
Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells.
###end article-title 59
###begin article-title 60
Regression of atherosclerosis: role of nitric oxide and apoptosis.
###end article-title 60
###begin article-title 61
N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor.
###end article-title 61
###begin article-title 62
Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction.
###end article-title 62
###begin article-title 63
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.
###end article-title 63
###begin article-title 64
Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy.
###end article-title 64
###begin article-title 65
###xml 46 54 <span type="species:ncbi:9606">patients</span>
High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells.
###end article-title 65
###begin article-title 66
Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes.
###end article-title 66
###begin article-title 67
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients.
###end article-title 67
###begin article-title 68
Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines.
###end article-title 68
###begin article-title 69
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes.
###end article-title 69
###begin article-title 70
###xml 75 81 <span type="species:ncbi:9606">humans</span>
Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.
###end article-title 70
###begin article-title 71
ADMA metabolism and clearance.
###end article-title 71
###begin article-title 72
The DDAH/ADMA/NOS pathway.
###end article-title 72
###begin article-title 73
###xml 22 27 <span type="species:ncbi:9606">human</span>
Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.
###end article-title 73
###begin article-title 74
Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins.
###end article-title 74
###begin article-title 75
Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence.
###end article-title 75
###begin article-title 76
Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function.
###end article-title 76
###begin article-title 77
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase.
###end article-title 77
###begin article-title 78
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance.
###end article-title 78
###begin article-title 79
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
###end article-title 79
###begin article-title 80
Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity.
###end article-title 80
###begin article-title 81
Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
###end article-title 81
###begin article-title 82
Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation.
###end article-title 82
###begin article-title 83
Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.
###end article-title 83
###begin article-title 84
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.
###end article-title 84
###begin article-title 85
Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.
###end article-title 85
###begin article-title 86
Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells.
###end article-title 86
###begin article-title 87
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
###end article-title 87
###begin article-title 88
Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
###end article-title 88
###begin article-title 89
Elevated glucose attenuates agonist- and flow-stimulated endothelial nitric oxide synthase activity in microvascular retinal endothelial cells.
###end article-title 89
###begin article-title 90
###xml 92 96 <span type="species:ncbi:10116">rats</span>
Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability.
###end article-title 90
###begin article-title 91
###xml 71 75 <span type="species:ncbi:10116">rats</span>
[Expression pattern of nitric oxide synthase in the retina of diabetic rats].
###end article-title 91
###begin article-title 92
###xml 79 84 <span type="species:ncbi:9606">human</span>
Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus.
###end article-title 92
###begin article-title 93
Possible involvement of nitric oxide in the progression of diabetic retinopathy.
###end article-title 93
###begin article-title 94
Small-conductance Cl- channels contribute to volume regulation and phagocytosis in microglia.
###end article-title 94
###begin article-title 95
Formation of an unfolding intermediate state of soluble chloride intracellular channel protein CLIC1 at acidic pH.
###end article-title 95
###begin article-title 96
The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle.
###end article-title 96
###begin article-title 97
Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.
###end article-title 97
###begin article-title 98
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 98
###begin article-title 99
The International HapMap Project.
###end article-title 99
###begin article-title 100
###xml 105 110 <span type="species:ncbi:9606">human</span>
Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma.
###end article-title 100
###begin article-title 101
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 101
###begin article-title 102
A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.
###end article-title 102
###begin article-title 103
Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix.
###end article-title 103
###begin p 104
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 104
###begin p 105
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by a grant from the Ophthalmic Research Institute of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 105

